health_text_en

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research   Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational…

thaipr.net

3 ต.ค. 65

ABILITY DIABETES GLOBAL – A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

ABILITY DIABETES-GLOBAL (ADG), is the World’s largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing head-to-head the Sirolimus eluting stent , Abluminus DES+ (Concept Medical Inc.) with the XIENCE family of DES (Abbott Cardiovascular). Diabetes has been the Achilles heel for any vascular interventional procedures and there is a clinical need for adequately […]

thaipr.net

30 ก.ย. 65

Kimberly Nelson Named President of Kemin Nutrisurance

Third-generation Nelson family member poised to lead the pet food and rendering technologies business Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, has named Kimberly Nelson, a third-generation member of Kemin’s founding family, as president […]

thaipr.net

30 ก.ย. 65

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration (FDA) […]

thaipr.net

30 ก.ย. 65

JDRF Announces Launch of Global Type 1 Diabetes Index

The first -of-its-kind index will raise awareness of the burden and unmet need of people living with type 1 diabetes around the world. JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health […]

thaipr.net

22 ก.ย. 65

Methuselah Foundation Unveils ELONgevity Protection to Support Human Longevity Initiatives, Provide Access to Promising Experimental Therapies

Dogelon Mars (ELON) will be the key for terminally ill participants to unlock investigational treatments that offer a fighting chance to overcome deadly diseases Methuselah Foundation Co-founder and CEO David Gobel announced the formation of the ELONgevity Protection Project to promote human anti-aging efforts and provide members diagnosed with terminal diseases access to experimental therapies […]

thaipr.net

21 ก.ย. 65

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in China The deal brings together Melinta’s innovation, Menarini’s cross-regional expertise in registration and marketing this asset, and SciClone’s development and commercial presence in China Menarini will receive a total payment of up to […]

thaipr.net

20 ก.ย. 65

MagicTouch SCB receives IDE approval for In-Stent Restenosis indication

The US FDA has granted an Investigational Device Exemption (IDE) approval for MagicTouch Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR). US FDA’s IDE approval allows the MagicTouch SCB to be used in a pivotal clinical study to support safety and effectiveness of this combination product. The data generated from this IDE clinical study will support a pre-market […]

thaipr.net

20 ก.ย. 65

First patient enrolled in Erectile Dysfunction prospective randomized study with SELUTION SLR

An 82-year-old Taiwanese man has become the first patient to be enrolled in the initial Erectile Dysfunction (ED) randomized clinical trial (RCT) involving SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon.   The PERFECT-SELUTION FIM (PElvic Revascularization For EreCTile dysfuction-SELUTION First-In-Man) study involves a total of 54 patients suffering from distal internal pudendal-penile artery stenotic disease and ED. They are…

thaipr.net

16 ก.ย. 65

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

Concept Medical announces the successful completion of the TRANSFORM 1 RCT (TReAtmeNt of Small coronary vessels: Randomized controlled trial FOR MagicTouch Sirolimus Coated Balloon). The Randomized Controlled Trial (RCT) was conceptualized with the aim of understanding how the treatment indications and applications of Drug Coated Balloon (DCB) in coronary artery disease (CAD) can be broadened. This prospective, randomized, multi-centre,…

thaipr.net

15 ก.ย. 65
1 … 25 26 27 28 29 … 73

Copyright © 2026 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.